[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Faculty Hospital Kralovske Vinohrady\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":161},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,79,112,135],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100640629","fertility-outcomes-after-antibiotic-treatment-in-women-with-chronic-endometritis-100640629",false,"NCT07603492","Fertility Outcomes After Antibiotic Treatment In Women With Chronic Endometritis","Monitoring of Reproductive Outcomes in Women With Chronic Endometritis: A Prospective Cohort Study on the Impact of Antibiotic Treatment on Fertility and Obstetric Outcomes","MORE","Inclusion Criteria\n\n* Female participants aged 18-40 years.\n* Diagnosis of infertility (primary or secondary infertility).\n* Indication for diagnostic hysteroscopy with endometrial biopsy as part of infertility evaluation.\n* Suspected or confirmed chronic endometritis.\n* Ability and willingness to provide written informed consent prior to any study-related procedures.\n* Willingness to undergo protocol-defined antibiotic treatment.\n* Willingness to comply with study procedures and follow-up assessments.\n* Agreement to reproductive outcome monitoring following treatment, including spontaneous conception and pregnancies achieved through assisted reproductive technologies (ART).\n\nExclusion Criteria\n\n* Age \\>40 years.\n* Current pregnancy.\n* Known hypersensitivity or contraindication to tetracycline antibiotics or other study-related antibiotic therapy without a suitable alternative treatment option.\n* Severe systemic disease or medical condition that, in the opinion of the investigator, could interfere with study participation, safety, or interpretation of study results.\n* Active malignant disease requiring systemic treatment.\n* HIV infection or other severe immunodeficiency disorder.\n* Acute pelvic inflammatory disease or clinically significant active genital tract infection requiring immediate treatment.\n* Previous participation in this study.\n* Inability to undergo planned hysteroscopy or endometrial biopsy.\n* Inability or unwillingness to comply with study procedures or follow-up requirements.\n* Failure or refusal to provide written informed consent.","FEMALE","18 Years","40 Years",{"count":21,"type":22},100,"ESTIMATED","2 Years","OBSERVATIONAL","Chronic endometritis (CE) is a long-lasting inflammation of the lining of the uterus. Many women with CE do not have symptoms, but the condition may affect fertility, embryo implantation, and pregnancy outcomes. CE is usually diagnosed during hysteroscopy, a procedure that allows doctors to look inside the uterus and collect a small tissue sample for laboratory testing.\n\nThe goal of this prospective cohort study is to learn how common CE is in women with infertility and to determine whether antibiotic treatment improves reproductive outcomes. The study will also examine whether hysteroscopic findings match laboratory-confirmed CE and whether certain findings can help doctors diagnose CE more accurately. In addition, researchers will study the types of bacteria found in the uterine lining and their possible relationship to fertility and pregnancy outcomes.\n\nThe main questions the study aims to answer are:\n\n* How common is chronic endometritis in women undergoing infertility evaluation?\n* Does antibiotic treatment improve fertility and pregnancy outcomes in women with CE?\n* Can hysteroscopic findings reliably predict CE confirmed by laboratory testing?\n* Are specific bacteria associated with poorer reproductive outcomes? Researchers will enroll approximately 100 women aged 18 to 40 years with diagnosed infertility who are scheduled for hysteroscopy and endometrial biopsy as part of infertility evaluation. Participants with severe systemic disease, pregnancy, inability to undergo hysteroscopy or antibiotic treatment, or allergy to study antibiotics without a suitable alternative will not be included.\n\nParticipants will:\n\n* Undergo diagnostic hysteroscopy and endometrial biopsy\n* Have tissue samples examined using histopathology and immunohistochemistry to identify CE\n* Receive standardized antibiotic treatment if CE is confirmed\n* Be followed for up to 12 months after treatment to monitor fertility outcomes\n* Continue follow-up during pregnancy, if pregnancy occurs, to assess pregnancy and delivery outcomes Researchers will evaluate spontaneous pregnancies, embryo transfer success, implantation rates, miscarriage rates, time to pregnancy, and live birth outcomes. Pregnancy complications such as preeclampsia, placental disorders, premature rupture of membranes, and preterm birth will also be recorded.\n\nThe study is expected to run from January 2026 through December 2029. Data collected during the study may help improve the diagnosis and treatment of chronic endometritis in women with infertility and may support better reproductive outcomes in clinical practice.",[27,28,29,30],"Endometritis","Infertility","Hysteroscopy","Pregnancy Disease","RECRUITING","2026-05-22",{"date":34,"type":35},"2026-05-27","ACTUAL",{"date":37,"type":35},"2026-01-01",{"date":39,"type":22},"2030-01-01",{"name":41,"class":42},"Faculty Hospital Kralovske Vinohrady","OTHER_GOV",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100597365","uhf-ecg-in-lbbb-and-response-to-crt-prediction-100597365","NCT07057544","UHF ECG in LBBB and Response to CRT Prediction","The Role of Ultra-high-frequency ECG in the Localization of Left Ventricular Conduction Disorders and Prediction of Response to Resynchronization Therapy","UHF BLOCK","Inclusion Criteria:\n\n* HF due to ischemic or non-ischemic cardiomyopathy\n* known coronary angiography\n* NYHA II-IV\n* LVEF ≤40%\n* non-RBBB QRSd lasting \\>130 ms (by automated measurement)\n* proximal LBBB proved by an invasive EP study or non-invasive dyssynchrony assessment in case such a method is confirmed to be non-inferior to an invasive EP study during the project\n\nExclusion Criteria:\n\n* Age ˂18 years\n* heart failure from reversible causes\n* Moderate to severe aortic stenosis\n* pregnancy\n* active myocarditis\n* hypertrophic cardiomyopathy\n* cardiac valve surgery in the last three months\n* myocardial infarction, PCI, or CABG in the last three months\n* severe valvular disease requiring intervention\n* severe atherosclerotic disease of the aorta and\u002For femoral arteries\n* life expectancy ˂1 year\n* known medical condition or contraindication causing potential complications for EP study","ALL",{"count":54,"type":22},200,"INTERVENTIONAL",[57],"NA","The main objective of the project is to demonstrate that in patients with heart failure and QRS complex of nonRBBB morphology lasting over 130 ms, UHF-ECG can differentiate patients with trueLBBB from IVCD better than existing approaches based on the assessment of QRS complex morphology and duration from 12-lead ECG.\n\nAnother goal of the proposed study is to demonstrate that trueLBBB patients will benefit more from CRT using left bundle branch pacing than from CRT using biventricular pacing.\n\nThe final aim of the project is to demonstrate that the echocardiographic and clinical response in patients with intraventricular conduction disturbance will be dependent on the degree of reduction in ventricular dyssynchrony after CRT.",[60,61,62,63],"Left Bundle Branch Block","Left Bundle Branch Area Pacing","Biventricular Pacing","Intraventricular Conduction Delay",[65,66,67,68,69],"left bundle branch block","resynchronization therapy","intraventricular conduction delay","left bundle branch pacing","biventricular pacing","2025-07-09",{"date":72,"type":35},"2025-07-14",{"date":74,"type":35},"2024-05-01",{"date":76,"type":22},"2027-12-31",{"name":41,"class":42},1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":88,"targetDuration":90,"studyType":24,"phases":4,"briefSummary":91,"conditions":92,"keywords":98,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":109,"leadSponsor":111,"locationsCount":78},"100577875","impact-of-delivery-method-elite-athletes-100577875","NCT06803979","Impact of Delivery Method Elite Athletes.","The Impact of Delivery Method on the Performance of Elite Athletes.","IDEA","Inclusion Criteria:\n\n\\- Elite female athletes meeting representation limits and included in national teams organized under the Czech Olympic Committee and individual sports federations.\n\nExclusion Criteria:\n\n\\- Any male",true,{"count":89,"type":22},500,"100 Years","Labor itself can occur spontaneously vaginally, with the help of extraction methods, or via cesarean section. It can also be planned or awaited for the spontaneous onset of uterine contractions. Each method has its advantages and disadvantages regarding potential damage to the pelvic floor and its stability in vaginal delivery or extraction methods, or concerning the stability of the abdominal wall with subsequent wound healing after a cesarean section.\n\nThe aim of the study is to retrospectively and prospectively determine the impact of the method of delivery on the performance of female athletes through a questionnaire study. Investigators would like to answer the question of whether cesarean delivery means a later return to training for athletes, whether pregnancy is problematic for female athletes in relation to their BMI, and whether pregnancy often signifies the end of a sports career for female athletes. The questionnaire also includes questions regarding overall women's health-menstrual cycle, incontinence, and mental health of female athletes. Prospectively, the questionnaire will be sent to all female athletes who meet representation limits once a year and for two years after retiring from the national team.",[93,94,95,96,97],"Delivery","Performance","Caesarean Section","Pregnancy","Athletes",[99,100,101,102,103,104],"delivery","performance","caesarean section","pregnancy","athletes","women health","2025-03-16",{"date":107,"type":35},"2025-03-18",{"date":105,"type":22},{"date":110,"type":22},"2040-01-01",{"name":41,"class":42},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":87,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":55,"phases":121,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":78},"100517374","the-effect-of-labor-on-intraocular-pressure-fluctuation-in-healthy-eyes-100517374","NCT06016712","The Effect of Labor on Intraocular Pressure Fluctuation in Healthy Eyes","ELIPFHE","Inclusion Criteria:\n\n* physiological pregnancy\n* primiparous women\n\nExclusion Criteria:\n\n* multiparous women\n* pathological pregnancy",{"count":120,"type":22},9,[57],"Glaucoma is a multifactorial disease, an important risk factor of which is increased intraocular pressure. Fluctuations in intraocular pressure are often associated with vaginal birth, although intraocular pressure during active pushing during stage II has never been measured.. The study will be conducted on a group of patients with healthy eyes on patients who have completely fine vision or have a small refractive error and are accustomed to wearing contact lenses. The measurement of intraocular pressure itself will be carried out using SENSIMED Triggerfish contact lenses, which measure pressure every 5 minutes for 30s. This period roughly corresponds to the duration of 1-2 contractions. Inclusion in the study will be offered to patients in the 35th to 37th week of pregnancy. Prior to measurement patients will be sent to an eye clinic for a detailed examination of both eyes, which includes measuring intraocular pressure. Subsequently, pregnancy checks will take place according to the standard scheme and in the standard scope. At the onset of uterine contractions, an ophthalmologic consultant will be called, which will measure intraocular pressure between contractions using the Tonopen device and put on SENSIMED Trigerfish contact lenses in combination with a local anesthetic. The patient will have these lenses until the end of the third stage of labor, i.e. 2 hours after the birth, when the lenses are removed. In the second stage of labor, continuous monitoring by a cardiotocograph will take place. Subsequently, the obtained data from the cardiotocograph and contact lenses will be evaluated and compared by a team of ophthalmologists and gynecologists, where the investigators will be able to assess the individual fluctuations in intraocular pressure depending on the individual contractions. The aim of the study is to demonstrate or disprove the risks to the glaucoma patient due to increased intraocular pressure during active pushing in combination with uterine contraction.",[124,93],"Intraocular Pressure",[126,99,102,127],"Intraocular pressure","glaucoma",{"date":129,"type":35},"2025-03-19",{"date":131,"type":35},"2023-08-08",{"date":133,"type":22},"2025-12-31",{"name":41,"class":42},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":52,"minAge":4,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":55,"phases":143,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":78},"100583355","phase-4-comparing-efficacy-of-8-week-and-12-week-faricimab-initial-follow-up-treatment-intervals-100583355","NCT06875245","Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals","Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals Following 4 Loading Doses - Prospective Randomised Study","Inclusion Criteria:\n\nActive treatment naïve CNV (Type 1, Type 2, or Type 3) in the macula including fovea diagnosed on OCT and OCTA\n\nBCVA between 70 to 35 ETDRS letters (approx. 20\u002F40 to 20\u002F200 Snellen equivalent) decrease in BCVA caused primarily by the CNV in the study eye\n\npresence of intra- or subretinal fluid or PED in the central 1 mm of the macula on the OCT\n\npatient capable of signing the informed consent\n\nExclusion Criteria:\n\nMyocardial Infarction or Stroke in the last 3 months\n\nPrevious or current conditions of the study eye:\n\n1. subretinal haemorrhage comprising more than 25% of the lesion in the study eye\n2. scar or fibrosis comprising more than 50% of the lesion in the study eye\n3. presence of retinal pigment epithelium (RPE) tears or ruptures in the central 1 mm of the macula in the study eye\n4. total lesion size more than 8 papillary diameters (PD) as per OCT and FP examination\n5. uncontrolled glaucoma in the study eye defined as IOP of more than 25 mmHg despite the antiglaucoma treatment\n6. idiopathic or autoimmune uveitis in the study eye\n7. other pathologies in the macula of the study eye unrelated to AMD which can be expected to influence the BCVA (e.g. macular hole, epiretinal membrane, etc.)\n\nk. significant opacities of the ocular media in the study eye including cataract, which can interfere with BCVA assessment or OCT examination\n\nn. diabetic retinopathy, diabetic macular edema or any other retinal vascular disease in the study eye\n\no. extraocular or periocular infection or inflammation (e.g. blepharitis, keratitis, conjunctivitis, scleritis, etc.) in any eye at the time of screening or baseline visit\n\np. any intraocular infection or inflammation in any eye during 12 weeks (84 days) before the screening visit\n\nq. allergy or hypersensitivity to any component contained in the study drug\n\nr. pregnant or breastfeeding women",{"count":21,"type":22},[144],"PHASE4","This is a prospective, randomized study that compares 8-week and 12-week follow-up intervals after the 4 monthly injections in the loading phase. Patients with active CNV confirmed on optical coherence tomography (OCT) and OCT angiography (OCTA) will be randomized into two groups and followed for 44 to 56 weeks.\n\nPatients in the first group will receive 4 injections of faricimab every 4 weeks, with the next visit and injection after 8 weeks, followed by a treat-and-extend regimen with a minimal interval of 8 weeks and a maximal interval of 16 weeks.\n\nPatients in the second group will also receive 4 loading doses with the next visit after an extended 12-week interval. Following treatment, patients in this group will be on the same treat-and-extend regimen as patients in the first group. The study will compare best corrected visual acuity (BCVA), central retinal thickness (CRT) on OCT, and the number of injections between both groups.",[147],"Wet Age-related Macular Degeneration",[149,150,151,152],"retina","amd","faricimab","macula","2025-03-10",{"date":155,"type":35},"2025-03-13",{"date":157,"type":35},"2023-03-31",{"date":159,"type":22},"2026-04",{"name":41,"class":42},""]